Heparin-induced thrombocytopenia: 2008 update

Area of Science:

• Pharmacology
• Hematology
• Immunology

Background:

• Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are widely used anticoagulants with increasing indications.
• Heparin-induced thrombocytopenia (HIT) is a recognized adverse effect of both UFH and LMWH.
• HIT is an immune-mediated condition that can lead to severe thrombotic events.

Purpose of the Study:

• To highlight the clinical significance of heparin-induced thrombocytopenia (HIT).
• To discuss the diagnostic criteria and management of HIT.
• To emphasize the importance of early recognition and intervention for HIT.

Main Methods:

• Review of current literature on heparin-induced thrombocytopenia (HIT).
• Analysis of diagnostic markers and clinical presentations of HIT.
• Discussion of treatment strategies for HIT.

Main Results:

• HIT is a prothrombotic condition associated with UFH and LMWH, potentially causing thrombosis, amputation, or death.
• HIT typically develops 4-14 days after heparin administration but can occur earlier with prior exposure or after discontinuation.
• A 50% reduction in platelet count from baseline is a key diagnostic indicator, replacing the necessity of thrombocytopenia itself.

Conclusions:

• Prompt diagnosis and management of HIT are critical.
• Discontinuation of the causative heparin agent is essential.
• Initiation of an alternative anticoagulant is necessary for prevention and treatment of HIT complications.